Press Release

LDC and Boehringer Ingelheim Join Forces to Discover a Novel Approach for the Treatment of Schizophrenia

Dortmund, May 11, 2016 – The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH and Boehringer Ingelheim International GmbH have signed an agreement providing Boehringer Ingelheim with the option to receive the exclusive rights to a new lead compound for the treatment of schizophrenia to be discovered and developed at the LDC.

The novel approach builds on ground-breaking research results from Prof. Moritz Rossner and his team at the Max Planck Institute of Experimental Medicine in Göttingen. He will work closely together with the LDC team to identify and optimize novel compounds with strong therapeutic potential and develop it further to the stage of a validated pharmaceutical lead with in vivo efficacy. Moritz Rossner holds also a Professorship at Ludwig Maximilians University, Munich and is a co-founder of Systasy Bioscience GmbH.

Schizophrenia is a chronic, severe and disabling mental disorder ranked among the 12 most debilitating diseases by the World Health Organization. It affects about 1 in 100 people worldwide, changing the way they behave, think and perceive the world. Although anti-psychotic medications and psychosocial interventions can effectively reduce symptoms and improve patients’ lives, there remains a strong need for new drugs truly addressing causative mechanisms and cognitive impairment.

“Schizophrenia is an incredibly complex disorder which dramatically changes the life of the individual affected,” says Prof. Rossner. “We believe our approach holds strong potential to improve the treatment options for patients, and this collaboration with the LDC and Boehringer Ingelheim is a great opportunity to advance it from our laboratory into pharmaceutical development.”

In this early discovery project Boehringer Ingelheim will take a seat on the project development team and will pay an option fee. In addition, the company will allocate internal resources to the program and support collaborating partners to strengthen the early development work. Once the project has attained proof-of-concept in relevant invivo models Boehringer Ingelheim can exclusively license the lead at pre-defined terms for subsequent preclinical and clinical development. Any revenue the LDC may receive from commercialization will be shared with the academic inventors and collaborating institutions.
“Since the LDC’s inception, we have been in close contact with Boehringer Ingelheim, establishing a relationship based on mutual trust over the years. We very much appreciate their expertise and commitment to driving forward innovative therapeutic approaches,” says Dr. Bert Klebl, CEO of the LDC. “It is a great pleasure for us to be launching our first joint project in the field of mental disorders, which we believe is often underestimated. We see strong commercial opportunities here, and there is already a strong line-up of promising projects in this area from our academic network.”

About the LDC

The Lead Discovery Center (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need.

The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads that reach initial proof-of-concept in animals. In close collaboration with high-profile partners from academia and industry, the LDC is building a strong and growing portfolio of small molecule programs with exceptional medical and commercial potential.

The LDC sustains a preferred partnership with the Max Planck Society and has formed alliances with AstraZeneca, Bayer, Merck Serono, Daiichi Sankyo, Qurient, Johnson & Johnson Innovation, Infinity Pharmaceuticals and Roche as well as leading translational drug discovery centers around the globe.

Further information at: www.lead-discovery.de

About Max Planck Innovation

Max Planck Innovation is responsible for the technology transfer of the Max Planck Society and, as such, serves as a link between industry and basic research. With its interdisciplinary team it advises and supports scientists in evaluating their inventions, filing patents, and founding companies. Max Planck Innovation offers the industry unique access to the innovations of the Max Planck Institutes, and therefore performs an important task: the transfer of basic research results into products, which contributes to economic and social progress.

Further information at: www.max-planck-innovation.de
Contact

Thomas Hegendörfer
T. +49.231.97 42 70 02
E. hegadoerfer@lead-discovery.de

Lead Discovery Center GmbH
Otto-Hahn-Straße 15
44227 Dortmund
Germany